» Articles » PMID: 34371949

The Homocysteine and Metabolic Syndrome: A Mendelian Randomization Study

Overview
Journal Nutrients
Date 2021 Aug 10
PMID 34371949
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Homocysteine (Hcy) is well known to be increased in the metabolic syndrome (MetS) incidence. However, it remains unclear whether the relationship is causal or not. Recently, Mendelian Randomization (MR) has been popularly used to assess the causal influence. In this study, we adopted MR to investigate the causal influence of Hcy on MetS in adults using three independent cohorts. We considered one-sample MR and two-sample MR. We analyzed one-sample MR in 5902 individuals (2090 MetS cases and 3812 controls) from the KARE and two-sample MR from the HEXA (676 cases and 3017 controls) and CAVAS (1052 cases and 764 controls) datasets to evaluate whether genetically increased Hcy level influences the risk of MetS. In observation studies, the odds of MetS increased with higher Hcy concentrations (odds ratio (OR) 1.17, 95%CI 1.12-1.22, < 0.01). One-sample MR was performed using two-stage least-squares regression, with an C677T and weighted Hcy generic risk score as an instrument. Two-sample MR was performed with five genetic variants (rs12567136, rs1801133, rs2336377, rs1624230, and rs1836883) by GWAS data as the instrumental variables. For sensitivity analysis, weighted median and MR-Egger regression were used. Using one-sample MR, we found an increased risk of MetS (OR 2.07 per 1-SD Hcy increase). Two-sample MR supported that increased Hcy was significantly associated with increased MetS risk by using the inverse variance weighted (IVW) method (beta 0.723, SE 0.119, and < 0.001), the weighted median regression method (beta 0.734, SE 0.097, and < 0.001), and the MR-Egger method (beta 2.073, SE 0.843, and 0.014) in meta-analysis. The MR-Egger slope showed no evidence of pleiotropic effects (intercept -0.097, 0.107). In conclusion, this study represented the MR approach and elucidates the significant relationship between Hcy and the risk of MetS in the Korean population.

Citing Articles

Associations of Circulating Biomarkers with Disease Risks: a Two-Sample Mendelian Randomization Study.

Elmas A, Spehar K, Do R, Castellano J, Huang K medRxiv. 2024; .

PMID: 39006413 PMC: 11245069. DOI: 10.1101/2024.06.30.24309729.


Associations of Circulating Biomarkers with Disease Risks: A Two-Sample Mendelian Randomization Study.

Elmas A, Spehar K, Do R, Castellano J, Huang K Int J Mol Sci. 2024; 25(13).

PMID: 39000484 PMC: 11242355. DOI: 10.3390/ijms25137376.


Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.

Sun W, Zhu X, Li J, Mei Y, Li W, Li J Front Pharmacol. 2024; 15:1410479.

PMID: 38919254 PMC: 11196770. DOI: 10.3389/fphar.2024.1410479.


Mendelian randomization study to investigate the causal relationship between plasma homocysteine and chronic obstructive pulmonary disease.

Hu Y, Tan P, Wang J, Zeng J, Li Q, Yan S World J Emerg Med. 2023; 14(5):367-371.

PMID: 37908800 PMC: 10613804. DOI: 10.5847/wjem.j.1920-8642.2023.078.


Metabolic disorders and risk of cardiovascular diseases: a two-sample mendelian randomization study.

Wang Z, Chen J, Zhu L, Jiao S, Chen Y, Sun Y BMC Cardiovasc Disord. 2023; 23(1):529.

PMID: 37907844 PMC: 10617200. DOI: 10.1186/s12872-023-03567-3.


References
1.
Huang T, Ren J, Huang J, Li D . Association of homocysteine with type 2 diabetes: a meta-analysis implementing Mendelian randomization approach. BMC Genomics. 2013; 14:867. PMC: 3878883. DOI: 10.1186/1471-2164-14-867. View

2.
Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

3.
Wang X, Ye P, Cao R, Yang X, Xiao W, Zhang Y . The association of homocysteine with metabolic syndrome in a community-dwelling population: homocysteine might be concomitant with metabolic syndrome. PLoS One. 2014; 9(11):e113148. PMC: 4234666. DOI: 10.1371/journal.pone.0113148. View

4.
Djuric D, Jakovljevic V, Zivkovic V, Srejovic I . Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems. Can J Physiol Pharmacol. 2018; 96(10):991-1003. DOI: 10.1139/cjpp-2018-0112. View

5.
Kumar J, Ingelsson E, Lind L, Fall T . No Evidence of a Causal Relationship between Plasma Homocysteine and Type 2 Diabetes: A Mendelian Randomization Study. Front Cardiovasc Med. 2015; 2:11. PMC: 4671343. DOI: 10.3389/fcvm.2015.00011. View